BiotechTube

ABBV-444

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dry Eye Syndrome

Conditions

Dry Eye Syndrome

Trial Timeline

Jun 27, 2023 → Oct 6, 2023

NCT ID
NCT05878067

About ABBV-444

ABBV-444 is a phase 3 stage product being developed by AbbVie for Dry Eye Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT05878067. Target conditions include Dry Eye Syndrome.

What happened to similar drugs?

20 of 20 similar drugs in Dry Eye Syndrome were approved

Approved (20) Terminated (4) Active (0)
✅high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibeYuhanApproved
✅Telmisartan 40mg + Rosuvastatin 20mg + Telmisartan 80mg + Rosuvastatin 20mg + Telmisartan 40mg, 80 mg + Rosuvastatin 20mgYuhanApproved
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
✅PrasugrelDaiichi SankyoApproved
✅30-day DAPT + Guideline-directed therapyDaiichi SankyoApproved
✅Gabapentin enacarbilAstellas PharmaApproved
✅Ramosetron + PlaceboAstellas PharmaApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05878067Phase 3Completed

Competing Products

20 competing products in Dry Eye Syndrome

See all competitors
ProductCompanyStageHype Score
NEX-18a injection + Azacitidine InjectionNanexa ABPhase 1
23
NAV5001 + DaTscanNavidea BiopharmaceuticalsPhase 3
22
JSP191Jasper TherapeuticsPhase 1
11
Humanized anti-CD117 Monoclonal Antibody (JSP191)Jasper TherapeuticsPhase 1
15
Tildacerfont + PlaceboSpruce BiosciencesPhase 2
17
agenT-797MiNK TherapeuticsPhase 1
19
SomatropinEli LillyPhase 3
40
GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase IIGT BiopharmaPhase 1/2
14
CTH120Connecta TherapeuticsPhase 1
19
CrovalimabChugai PharmaceuticalPhase 3
44
RAY121Chugai PharmaceuticalPhase 1
36
Crovalimab + Placebo + Intravenous immunoglobulin therapyChugai PharmaceuticalPhase 3
32
CrovalimabChugai PharmaceuticalPhase 3
44
RAY121Chugai PharmaceuticalPhase 1
36
YH14659 + clopidogrel & aspirinYuhanPhase 1
29
high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibeYuhanApproved
43
YH14659 + clopidogrel & aspirinYuhanPhase 1
29
Telmisartan 40mg + Rosuvastatin 20mg + Telmisartan 80mg + Rosuvastatin 20mg + Telmisartan 40mg, 80 mg + Rosuvastatin 20mgYuhanApproved
35
Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
43
clopidogrel + prasugrelDaiichi SankyoPhase 1
21